Intra-Cellular Therapies jumps after J&J to buy co for $14.6 billion
** Shares of Intra-Cellular Therapies ITCI.O rise 35.6% to
$128.65 premarket
** Johnson & Johnson JNJ.N will buy ITCI for around $14.6
billion
** JNJ will buy all of ITCI shares for $132/share,
representing a 39% premium to its Friday closing price
** ITCI rose 16.6% in 2024
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
Recent news on Intra-Cellular Therapies
See all newsBrief: Intra-Cellular Therapies stockholder filed lawsuit against co, board in NY Supreme Court
Intra-Cellular Therapies Inc reports results for the quarter ended December 31 - Earnings Summary
U.S. RESEARCH ROUNDUP-Apple, Caterpillar, Visa
Street View: New drug launches, ITCI deal to boost J&J's growth
J&J beats quarterly sales and profit estimates on cancer drug sales (updated)